This ASX healthcare stock is up 12% in 2 days since All Ords inclusion: Should you buy?

The latest member of the All Ordinaries index is getting some love this week.

| More on:
A man wearing a white coat and glasses is wide-mouthed in surprise.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

4DMedical Ltd (ASX: 4DX) shares are having another positive session.

At one stage today, the ASX healthcare stock was up as much as 7.5% to 78 cents.

When its shares hit that level, it meant they were up 12% in the space of just two days.

Why is this ASX healthcare stock jumping this week?

The catalyst for this rise has been news that the company's shares will be added to the All Ordinaries index later this month.

According to the update from S&P Dow Jones Indices, the medical research technology company is one of a number of new additions that will join the famous All Ordinaries index at the next quarterly rebalance on 18 March.

Furthermore, it will also join the S&P/ASX All Technology Index on the same day in the place of the ejected FINEOS Corporation Holdings PLC (ASX: FCL).

Is this good news?

Generally speaking, this can be very good news for a company's share price.

That's because fund managers often have restrictions on the shares they can buy. This is to stop them from risking client funds in speculative investments.

It's possible that some fund managers have investment mandates that allow them to invest in All Ordinaries shares. So, if they have been waiting to grab a piece of this ASX healthcare stock, this rebalance will allow them to finally press the buy button.

In addition, index funds that track the All Ordinaries or S&P/ASX All Technology Index will need to buy shares to reflect the changes.

Should you invest?

Bell Potter is very positive on the company, though it sees it as a higher risk option.

The broker currently has a speculative buy rating and $1.10 price target on the ASX healthcare stock.

This implies potential upside of over 40% for investors from current levels.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this fund manager is all in on Pro Medicus shares and recently increased his bet

This high-flying stock has suffered from turbulence.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Why I'm taking a closer look at ResMed shares

The ResMed share price hasn’t escaped recent market volatility. Is it time to buy?

Read more »

Health professional working on his laptop.
Healthcare Shares

Trump 2.0: Macquarie's take on the winners and losers in Australian healthcare

Let's see what the broker is saying about these healthcare stocks.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Own CSL shares? You're getting a dividend paycheque today

There's a silver lining to today's sell-off.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

How this Trump appointee could pressure the CSL share price

A leading expert believes Donald Trump isn’t doing CSL shareholders any favours.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Top broker says Mesoblast shares can rocket 100%

Big returns could be on offer from this biotech according to Bell Potter.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

Forget Trump! Here are 3 reasons to buy this $32 billion ASX 200 healthcare share today

A leading expert forecasts more growth ahead for this $32 billion ASX 200 healthcare company.

Read more »

A scientist examining test results.
Healthcare Shares

1 ASX dividend stock down 43% I'd buy right now

This business could provide both dividends and growing, defensive earnings.

Read more »